P253 ARV-471, a PROTAC® estrogen receptor (ER) degrader in advanced ER+/human epidermal growth factor receptor 2 (HER2)- breast cancer: phase 2 expansion (VERITAC) of a phase 1/2 study

Autor: Hurvitz, S.A, Schott, A.F, Ma, C., Hamilton, E.P, Nanda, R., Zahrah, G., Hunter, N., Tan, A.R, Telli, M.L, Mesias, J.A., Jeselsohn, R., Munster, P., Lu, H., Gedrich, R., Mather, C., Parameswaran, J., Han, H.S, Wirth, S.
Zdroj: In The Breast April 2023 68 Supplement:S116-S116
Databáze: ScienceDirect
Externí odkaz: